Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
TEVA · NYSE · Healthcare
Fundamental quality
49
out of 100
Teva Pharmaceutical Industries Ltd's profile is defined by leverage: it carries high debt (6.75× EBITDA) on thin margins (4.1%), which makes it more sensitive to rates and the cycle. On fundamental quality it scores 49 out of 100, profiling it as a company with demanding fundamentals. Its weakest area is its financial strength (net debt 6.75× EBITDA). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Teva is the world's largest generic-drug maker, the Israeli company that copies medicines when patents expire, plus a growing portfolio of its own branded drugs. It has spent a decade purging the debt and litigation of its years of unbridled expansion.
EPS growth: 10.7% · Revenue growth: 0.7%
Net margin: 4.1% · ROE: 9.1% · ROIC: 6.2%
Net debt/EBITDA: 6.75x · FCF: 7.8%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its profitability weighs in its favor, while its financial strength drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 16,659 | -3,990 | 638 | 25,987 |
| 2021 | 15,878 | 417 | 236 | 22,356 |
| 2022 | 14,925 | -2,446 | 1,042 | 20,551 |
| 2023 | 15,846 | -559 | 842 | 18,312 |
| 2024 | 16,544 | -1,639 | 749 | 16,279 |
| 2025 | 17,258 | 1,410 | 1,148 | 15,092 |
Between 2020 and 2025, revenue went from $16,659M to $17,258M (+4%) and net income went from -$3,990M to $1,410M (+135%). It has also reduced its net debt over the period.
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$0
per share, yearly
0.7% of free cash flow
Payout
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Teva Pharmaceutical Industries Ltd cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Teva Pharmaceutical Industries Ltd a good company to invest in?
In terms of business quality, Teva Pharmaceutical Industries Ltd scores 49 out of 100 in our analysis, placing it as a company with demanding fundamentals. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Teva Pharmaceutical Industries Ltd a profitable company?
Teva Pharmaceutical Industries Ltd is profitable, with a net margin of 4.1%, though a thin one.
Does Teva Pharmaceutical Industries Ltd have a lot of debt?
Yes, its leverage is high: net debt is 6.75 times its EBITDA.
Is Teva Pharmaceutical Industries Ltd growing?
Its revenue has grown 0.7% annualized in recent years and its earnings per share 10.7%.
Does Teva Pharmaceutical Industries Ltd generate cash?
Yes. It converts about 7.8% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Community Health Systems (CYH) · Hims & Hers Health (HIMS) · Oscar Health (OSCR) · Recursion Pharmaceuticals (RXRX) · Eli Lilly (LLY) · UnitedHealth (UNH) · see more →
The best Healthcare stocks by our model →
Compare Teva Pharmaceutical Industries Ltd with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Teva Pharmaceutical Industries Ltd's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.